Major Depressive Disorder (MDD) represents one of the most significant challenges in modern psychiatry, affecting approximately 280 million people globally and constituting a leading cause of disability worldwide. Despite advances in treatment approaches, achieving and maintaining remission remains a complex clinical challenge, with only about 30-40% of patients achieving full remission after initial treatment.
Major Depressive Disorder (MDD) represents one of the most significant challenges in modern psychiatry, affecting approximately 280 million people globally and constituting a leading cause of disability worldwide. Despite advances in treatment approaches, achieving and maintaining remission remains a complex clinical challenge, with only about 30-40% of patients achieving full remission after initial treatment.
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Kasimov A.A. | ! | Samarkand State Medical University |
| 2 | Mamurova M.M. | ! | Samarkand State Medical University |
| 3 | Khasanova K.T. | ! | Samarkand State Medical University |
| 4 | Egamberdieva Z.P. | ! | Samarkand State Medical University |
| 5 | Ankabayev S.M. | ! | Samarkand State Medical University |
| № | Ҳавола номи |
|---|---|
| 1 | 1.Anderson KM, Collins DR. Neurotransmitter systems in major depression: from pathophysiology to remission. Nature Reviews Neuroscience. 2023;24(8):456-471.2.Zhang L, Thompson RD, Chen X. Neurobiological markers of treatment response in major depressive disorder: A systematic review and meta-analysis. Journal of Affective Disorders. 2024;301:45-58.3.Martinez-Garcia P, Wilson KB. The role of monoamine systems in achieving and maintaining remission in MDD. Molecular Psychiatry. 2023;28(5):2234-2246.4.Patel S, Johnson R, Smith A. Synaptic plasticity and neurotransmitter dynamics during depression recovery. Neuroscience & Biobehavioral Reviews. 2023;145:104-118.5.Lee JH, Kim SY, Park HS. Longitudinal changes in neurotransmitter profiles during successful antidepressant treatment. Biological Psychiatry. 2024;95(2):167-179.6.Brown RD, Davis KL. Neuroimaging correlates of neurotransmitter function in MDD remission. American Journal of Psychiatry. 2023;180(6):512-525.7.Williams P, Taylor R, Roberts M. Predictivebiomarkersof treatment response in major depression: Focus on neurotransmitter systems. The Lancet Psychiatry. 2023;10(8):678-690.8.Harrison PL, Walker JD. Neurotransmitter interactions in depression: Implications for achieving remission. Neuropsychopharmacology. 2024;49(3):334-347.9.Lopez-Garcia F, Thompson B. Clinical outcomes and neurotransmitter changes during remission in major depressive disorder. Journal of Clinical Psychiatry. 2023;84(4):223-235.10.White RS, Johnson BT. Molecular mechanisms of antidepressant response: A focus on synaptic neurotransmission. Trends in Neurosciences. 2023;46(12):901-915.11.Peterson AK, Collins MS. The neurobiology of remission in major depression: Current evidence and future directions. Psychological Medicine. 2024;54(1):78-89.12.Chen H, Wang Y, Liu X. Neurotransmitter-based stratification of treatment response in MDD: A prospective study. European Neuropsychopharmacology. 2023;68:45-57.13.Miller RD, Thompson PL. Neuroplasticity and neurotransmitter adaptation during successful depression treatment. Progress in Neurobiology. 2023;220:102327.14.Baker JT, Dougherty DD. Neural circuit reorganization in MDD remission: Role of neurotransmitter systems. Neuropsychopharmacology Reviews. 2024;49(1):156-169. |